Leukemia is the most common blood cancer, it affects adults 10 times more often than children, but it is the most common childhood cancer. Leukemia causes the bone marrow to produce abnormal white blood cells, these cells do not die when they should and may crowd normal healthy cells, making healthy cells unable to function. In Acute Leukemia, the leukemic cells cannot do the white blood cells functions and the number of leukemic cells increases rapidly. Acute Leukemia usually worsens quickly. Generally men are more likely to be diagnosed with Leukemia than women. The number of new cases diagnosed each year has remained steady for the past 20 years, while the morality rates have greatly decreased. There are many risk factors that greatly increase the odds of developing leukemia such as smoking, chemical exposure, radiation and certain inherited diseases.
Acute Leukemia Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Acute Leukemia below!
For more information on how to use Laverne, please read the How to Guide.
We have 2458 products for the study of Acute Leukemia that can be applied to Chromatin Immunoprecipitation, Flow Cytometry, Western Blot, Immunohistochemistry, Immunocytochemistry/Immunofluorescence from our catalog of antibodies and ELISA kits.
Acute Leukemia is also known as Acute Leukaemia, Acute Leukemia, Disease, Leukaemia Acute, Leukemia Acute, Leukemia, Acute.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.